Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments.

Noad RJ, Simpson K, Fooks AR, Hewson R, Gilbert SC, Stevens MP, Hosie MJ, Prior J, Kinsey AM, Entrican G, Simpson A, Whitty CJM, Carroll MW.

Vaccine. 2019 Oct 8;37(43):6241-6247. doi: 10.1016/j.vaccine.2019.09.009. Epub 2019 Sep 12.

2.

Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge.

McMahon M, Asthagiri Arunkumar G, Liu WC, Stadlbauer D, Albrecht RA, Pavot V, Aramouni M, Lambe T, Gilbert SC, Krammer F.

Front Immunol. 2019 Aug 21;10:2005. doi: 10.3389/fimmu.2019.02005. eCollection 2019.

3.

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine.

Folegatti PM, Bellamy D, Roberts R, Powlson J, Edwards NJ, Mair CF, Bowyer G, Poulton I, Mitton CH, Green N, Berrie E, Lawrie AM, Hill AVS, Ewer KJ, Hermon-Taylor J, Gilbert SC.

Vaccines (Basel). 2019 May 15;7(2). pii: E40. doi: 10.3390/vaccines7020040.

4.

Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components.

Fedosyuk S, Merritt T, Peralta-Alvarez MP, Morris SJ, Lam A, Laroudie N, Kangokar A, Wright D, Warimwe GM, Angell-Manning P, Ritchie AJ, Gilbert SC, Xenopoulos A, Boumlic A, Douglas AD.

Vaccine. 2019 Apr 29. pii: S0264-410X(19)30532-8. doi: 10.1016/j.vaccine.2019.04.056. [Epub ahead of print]

PMID:
31047679
5.

Vaccine platforms for the prevention of Lassa fever.

Purushotham J, Lambe T, Gilbert SC.

Immunol Lett. 2019 Apr 23. pii: S0165-2478(19)30048-3. doi: 10.1016/j.imlet.2019.03.008. [Epub ahead of print] Review.

6.

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line.

Folegatti PM, Bellamy D, Flaxman A, Mair C, Ellis C, Ramon RL, Ramos Lopez F, Mitton C, Baker M, Poulton I, Lawrie A, Roberts R, Minassian A, Ewer KJ, Evans TG, Hill AVS, Gilbert SC.

Vaccines (Basel). 2019 Mar 22;7(1). pii: E33. doi: 10.3390/vaccines7010033.

7.

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal.

Venkatraman N, Ndiaye BP, Bowyer G, Wade D, Sridhar S, Wright D, Powlson J, Ndiaye I, Dièye S, Thompson C, Bakhoum M, Morter R, Capone S, Del Sorbo M, Jamieson S, Rampling T, Datoo M, Roberts R, Poulton I, Griffiths O, Ballou WR, Roman F, Lewis DJM, Lawrie A, Imoukhuede E, Gilbert SC, Dieye TN, Ewer KJ, Mboup S, Hill AVS.

J Infect Dis. 2019 Apr 8;219(8):1187-1197. doi: 10.1093/infdis/jiy639.

8.

A naturally protective epitope of limited variability as an influenza vaccine target.

Thompson CP, Lourenço J, Walters AA, Obolski U, Edmans M, Palmer DS, Kooblall K, Carnell GW, O'Connor D, Bowden TA, Pybus OG, Pollard AJ, Temperton NJ, Lambe T, Gilbert SC, Gupta S.

Nat Commun. 2018 Sep 21;9(1):3859. doi: 10.1038/s41467-018-06228-8.

9.

Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors.

López-Camacho C, Abbink P, Larocca RA, Dejnirattisai W, Boyd M, Badamchi-Zadeh A, Wallace ZR, Doig J, Velazquez RS, Neto RDL, Coelho DF, Kim YC, Donald CL, Owsianka A, De Lorenzo G, Kohl A, Gilbert SC, Dorrell L, Mongkolsapaya J, Patel AH, Screaton GR, Barouch DH, Hill AVS, Reyes-Sandoval A.

Nat Commun. 2018 Jun 22;9(1):2441. doi: 10.1038/s41467-018-04859-5.

10.

Corrigendum to "Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults" [EBioMedicine 29 (2018) 146-154].

Coughlan L, Sridhar S, Payne R, Edmans M, Milicic A, Venkatraman N, Lugonja B, Clifton L, Qi C, Folegatti PM, Lawrie AM, Roberts R, de Graaf H, Sukhtankar P, Faust SN, Lewis DJM, Lambe T, Hill AVS, Gilbert SC.

EBioMedicine. 2018 May;31:321. doi: 10.1016/j.ebiom.2018.05.001. Epub 2018 May 5. No abstract available.

11.

Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults.

Coughlan L, Sridhar S, Payne R, Edmans M, Milicic A, Venkatraman N, Lugonja B, Clifton L, Qi C, Folegatti PM, Lawrie AM, Roberts R, de Graaf H, Sukhtankar P, Faust SN, Lewis DJM, Lambe T, Hill A, Gilbert SC.

EBioMedicine. 2018 Mar;29:146-154. doi: 10.1016/j.ebiom.2018.02.011. Epub 2018 Feb 15. Erratum in: EBioMedicine. 2018 May 4;:.

12.

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.

Bliss CM, Bowyer G, Anagnostou NA, Havelock T, Snudden CM, Davies H, de Cassan SC, Grobbelaar A, Lawrie AM, Venkatraman N, Poulton ID, Roberts R, Mange PB, Choudhary P, Faust SN, Colloca S, Gilbert SC, Nicosia A, Hill AVS, Ewer KJ.

Sci Rep. 2018 Feb 21;8(1):3390. doi: 10.1038/s41598-018-21630-4.

13.

Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model.

Munster VJ, Wells D, Lambe T, Wright D, Fischer RJ, Bushmaker T, Saturday G, van Doremalen N, Gilbert SC, de Wit E, Warimwe GM.

NPJ Vaccines. 2017 Oct 16;2:28. doi: 10.1038/s41541-017-0029-1. eCollection 2017.

14.

Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge.

Tully CM, Chinnakannan S, Mullarkey CE, Ulaszewska M, Ferrara F, Temperton N, Gilbert SC, Lambe T.

J Immunol. 2017 Jul 19. pii: ji1600939. doi: 10.4049/jimmunol.1600939. [Epub ahead of print]

PMID:
28724579
15.

Development of an objective gene expression panel as an alternative to self-reported symptom scores in human influenza challenge trials.

Muller J, Parizotto E, Antrobus R, Francis J, Bunce C, Stranks A, Nichols M, McClain M, Hill AVS, Ramasamy A, Gilbert SC.

J Transl Med. 2017 Jun 8;15(1):134. doi: 10.1186/s12967-017-1235-3.

16.

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.

Alharbi NK, Padron-Regalado E, Thompson CP, Kupke A, Wells D, Sloan MA, Grehan K, Temperton N, Lambe T, Warimwe G, Becker S, Hill AVS, Gilbert SC.

Vaccine. 2017 Jun 27;35(30):3780-3788. doi: 10.1016/j.vaccine.2017.05.032. Epub 2017 Jun 1.

17.

Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology.

Gilbert SC, Warimwe GM.

Vaccine. 2017 Aug 16;35(35 Pt A):4461-4464. doi: 10.1016/j.vaccine.2017.04.085. Epub 2017 May 30. Review.

18.

Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.

Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS.

Sci Rep. 2017 Apr 19;7:46621. doi: 10.1038/srep46621.

19.

Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector.

Pavot V, Sebastian S, Turner AV, Matthews J, Gilbert SC.

Methods Mol Biol. 2017;1581:97-119. doi: 10.1007/978-1-4939-6869-5_6.

PMID:
28374245
20.

Simian adenoviruses as vaccine vectors.

Morris SJ, Sebastian S, Spencer AJ, Gilbert SC.

Future Virol. 2016 Sep;11(9):649-659. doi: 10.2217/fvl-2016-0070. Epub 2016 Sep 15. Review.

21.

What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins.

Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I, Chen W, Wines B, Hogarth PM, Lambe T, Gilbert SC, Parsons MS, Kent SJ.

EBioMedicine. 2016 Jun;8:277-290. doi: 10.1016/j.ebiom.2016.04.029. Epub 2016 Apr 28.

22.

Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid.

Lambe T, Rampling T, Samuel D, Bowyer G, Ewer KJ, Venkatraman N, Edmans M, Dicks S, Hill AV, Tedder RS, Gilbert SC.

Open Forum Infect Dis. 2016 Feb 22;3(1):ofw031. doi: 10.1093/ofid/ofw031. eCollection 2016 Jan.

23.

Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.

Mullin J, Ahmed MS, Sharma R, Upile N, Beer H, Achar P, Puksuriwong S, Ferrara F, Temperton N, McNamara P, Lambe T, Gilbert SC, Zhang Q.

Vaccine. 2016 Mar 29;34(14):1688-95. doi: 10.1016/j.vaccine.2016.02.028. Epub 2016 Feb 20.

PMID:
26902548
24.

Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever.

Warimwe GM, Gesharisha J, Carr BV, Otieno S, Otingah K, Wright D, Charleston B, Okoth E, Elena LG, Lorenzo G, Ayman el-B, Alharbi NK, Al-dubaib MA, Brun A, Gilbert SC, Nene V, Hill AV.

Sci Rep. 2016 Feb 5;6:20617. doi: 10.1038/srep20617.

25.

Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter.

Alharbi NK, Spencer AJ, Salman AM, Tully CM, Chinnakannan SK, Lambe T, Yamaguchi Y, Morris SJ, Orubu T, Draper SJ, Hill AV, Gilbert SC.

Vaccine. 2016 Jan 2;34(1):49-55. doi: 10.1016/j.vaccine.2015.11.028. Epub 2015 Nov 24.

PMID:
26616553
26.

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice.

Dicks MD, Spencer AJ, Coughlan L, Bauza K, Gilbert SC, Hill AV, Cottingham MG.

Sci Rep. 2015 Nov 18;5:16756. doi: 10.1038/srep16756.

27.

Recombinant modified vaccinia virus Ankara-based malaria vaccines.

Sebastian S, Gilbert SC.

Expert Rev Vaccines. 2016;15(1):91-103. doi: 10.1586/14760584.2016.1106319. Epub 2015 Oct 29. Review.

PMID:
26511884
28.

Adenovirus-vectored Ebola vaccines.

Gilbert SC.

Expert Rev Vaccines. 2015;14(10):1347-57. doi: 10.1586/14760584.2015.1077122. Epub 2015 Aug 11. Review.

PMID:
26289977
29.

Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.

Kapulu MC, Da DF, Miura K, Li Y, Blagborough AM, Churcher TS, Nikolaeva D, Williams AR, Goodman AL, Sangare I, Turner AV, Cottingham MG, Nicosia A, Straschil U, Tsuboi T, Gilbert SC, Long CA, Sinden RE, Draper SJ, Hill AV, Cohuet A, Biswas S.

Sci Rep. 2015 Jun 11;5:11193. doi: 10.1038/srep11193.

30.

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.

Alharbi NK, Spencer AJ, Hill AV, Gilbert SC.

PLoS One. 2015 Jun 8;10(6):e0128626. doi: 10.1371/journal.pone.0128626. eCollection 2015.

31.

Investigation of IRES Insertion into the Genome of Recombinant MVA as a Translation Enhancer in the Context of Transcript Decapping.

Alharbi NK, Chinnakannan SK, Gilbert SC, Draper SJ.

PLoS One. 2015 May 26;10(5):e0127978. doi: 10.1371/journal.pone.0127978. eCollection 2015.

32.

Corrections. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases.

Tully CM, Lambe T, Gilbert SC, Hill AV.

Lancet Infect Dis. 2015 Mar;15(3):263. doi: 10.1016/S1473-3099(14)70967-3. Epub 2015 Jan 20. No abstract available.

PMID:
25749220
33.

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.

Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krähling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbé G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV.

N Engl J Med. 2016 Apr 28;374(17):1635-46. doi: 10.1056/NEJMoa1411627. Epub 2015 Jan 28.

34.

The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.

Dicks MD, Guzman E, Spencer AJ, Gilbert SC, Charleston B, Hill AV, Cottingham MG.

Vaccine. 2015 Feb 25;33(9):1121-8. doi: 10.1016/j.vaccine.2015.01.042. Epub 2015 Jan 25.

35.

Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies.

Hodgson SH, Douglas AD, Edwards NJ, Kimani D, Elias SC, Chang M, Daza G, Seilie AM, Magiri C, Muia A, Juma EA, Cole AO, Rampling TW, Anagnostou NA, Gilbert SC, Hoffman SL, Draper SJ, Bejon P, Ogutu B, Marsh K, Hill AV, Murphy SC.

Malar J. 2015 Jan 28;14:33. doi: 10.1186/s12936-015-0541-6.

36.

Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases.

Tully CM, Lambe T, Gilbert SC, Hill AV.

Lancet Infect Dis. 2015 Mar;15(3):356-9. doi: 10.1016/S1473-3099(14)71071-0. Epub 2015 Jan 14. Review. Erratum in: Lancet Infect Dis. 2015 Mar;15(3):263.

PMID:
25595637
37.

Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.

Pavot V, Berthet M, Rességuier J, Legaz S, Handké N, Gilbert SC, Paul S, Verrier B.

Nanomedicine (Lond). 2014 Dec;9(17):2703-18. doi: 10.2217/nnm.14.156.

PMID:
25529572
38.

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.

de Barra E, Hodgson SH, Ewer KJ, Bliss CM, Hennigan K, Collins A, Berrie E, Lawrie AM, Gilbert SC, Nicosia A, McConkey SJ, Hill AV.

PLoS One. 2014 Dec 18;9(12):e115161. doi: 10.1371/journal.pone.0115161. eCollection 2014.

39.

Immunity, safety and protection of an Adenovirus 5 prime--Modified Vaccinia virus Ankara boost subunit vaccine against Mycobacterium avium subspecies paratuberculosis infection in calves.

Bull TJ, Vrettou C, Linedale R, McGuinnes C, Strain S, McNair J, Gilbert SC, Hope JC.

Vet Res. 2014 Oct 29;45:112. doi: 10.1186/s13567-014-0112-9.

40.

Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.

Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, de Barra E, Havelock T, Bowyer G, Poulton ID, de Cassan S, Longley R, Illingworth JJ, Douglas AD, Mange PB, Collins KA, Roberts R, Gerry S, Berrie E, Moyle S, Colloca S, Cortese R, Sinden RE, Gilbert SC, Bejon P, Lawrie AM, Nicosia A, Faust SN, Hill AV.

J Infect Dis. 2015 Apr 1;211(7):1076-86. doi: 10.1093/infdis/jiu579. Epub 2014 Oct 21.

41.

4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaques.

Spencer AJ, Furze J, Honeycutt JD, Calvert A, Saurya S, Colloca S, Wyllie DH, Gilbert SC, Bregu M, Cottingham MG, Hill AV.

PLoS One. 2014 Aug 20;9(8):e105520. doi: 10.1371/journal.pone.0105520. eCollection 2014.

42.

Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs.

Busquets N, Lorenzo G, López-Gil E, Rivas R, Solanes D, Galindo-Cardiel I, Abad FX, Rodríguez F, Bensaid A, Warimwe G, Gilbert SC, Domingo M, Brun A.

Antiviral Res. 2014 Aug;108:165-72. doi: 10.1016/j.antiviral.2014.05.020. Epub 2014 Jun 14.

PMID:
24933081
43.

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

Kimani D, Jagne YJ, Cox M, Kimani E, Bliss CM, Gitau E, Ogwang C, Afolabi MO, Bowyer G, Collins KA, Edwards N, Hodgson SH, Duncan CJ, Spencer AJ, Knight MG, Drammeh A, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Soipei P, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Chilengi R, Bojang K, Flanagan KL, Hill AV, Urban BC, Ewer KJ.

Mol Ther. 2014 Nov;22(11):1992-2003. doi: 10.1038/mt.2014.109. Epub 2014 Jun 16.

44.

External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance.

Murphy SC, Hermsen CC, Douglas AD, Edwards NJ, Petersen I, Fahle GA, Adams M, Berry AA, Billman ZP, Gilbert SC, Laurens MB, Leroy O, Lyke KE, Plowe CV, Seilie AM, Strauss KA, Teelen K, Hill AV, Sauerwein RW.

PLoS One. 2014 May 16;9(5):e97398. doi: 10.1371/journal.pone.0097398. eCollection 2014.

45.

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.

Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, Gilbert SC.

Mol Ther. 2014 Mar;22(3):668-674. doi: 10.1038/mt.2013.284. Epub 2013 Dec 30.

46.

Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.

Warimwe GM, Lorenzo G, Lopez-Gil E, Reyes-Sandoval A, Cottingham MG, Spencer AJ, Collins KA, Dicks MD, Milicic A, Lall A, Furze J, Turner AV, Hill AV, Brun A, Gilbert SC.

Virol J. 2013 Dec 5;10:349. doi: 10.1186/1743-422X-10-349.

47.

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.

Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AV.

Nat Commun. 2013;4:2836. doi: 10.1038/ncomms3836.

48.

A multi-antigenic adenoviral-vectored vaccine improves BCG-induced protection of goats against pulmonary tuberculosis infection and prevents disease progression.

Pérez de Val B, Vidal E, Villarreal-Ramos B, Gilbert SC, Andaluz A, Moll X, Martín M, Nofrarías M, McShane H, Vordermeier HM, Domingo M.

PLoS One. 2013 Nov 21;8(11):e81317. doi: 10.1371/journal.pone.0081317. eCollection 2013.

49.

The effectiveness of enzymic irrigation in removing a nutrient-stressed endodontic multispecies biofilm.

Niazi SA, Clark D, Do T, Gilbert SC, Foschi F, Mannocci F, Beighton D.

Int Endod J. 2014 Aug;47(8):756-68. doi: 10.1111/iej.12214. Epub 2014 Jan 9.

50.

A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.

López-Gil E, Lorenzo G, Hevia E, Borrego B, Eiden M, Groschup M, Gilbert SC, Brun A.

PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2309. doi: 10.1371/journal.pntd.0002309. Print 2013.

Supplemental Content

Loading ...
Support Center